Amgen-Roche Patent Brawl Over Mircera Produces Mixed Ruling At Appeals Court
This article was originally published in The Pink Sheet Daily
Federal Circuit proves it can be as unpredictable for biologics as it often is for small molecules.
You may also be interested in...
Roche will not launch its anemia drug Mircera in the U.S. until Amgen's latest patent expires in 2015 unless it obtains a license.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.